• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Jaguar Animal Health seeks MUMS designation from FDA to expand canine diarrhea treatment

February 16, 2022

Jaguar Animal Health has submitted a request to the FDA’s Center for Veterinary Medicine for Minor Use/Minor Species (MUMS) designation for the company's drug candidate crofelemer (Canalevia) for treatment of exercise-induced diarrhea (EID) in dogs. The oral, plant-based drug was conditionally approved by the FDA in December 2021 for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

"MUMS designation is a status similar to ‘orphan drug' status for human drugs, and it makes the proposed intended use of a MUMS drug eligible for specific incentives supporting product approval or conditional approval," said Michael Guy, DVM, MS, PhD, Jaguar Health's vice president of preclinical and nonclinical studies, in a company press release.

Receipt of MUMS designation for crofelemer for EID in dogs provide the company with eligibility to apply for federal grants related to development costs, and allow Jaguar Animal Health with a longer period—7 years—of marketing exclusivity following conditional approval of the drug for EID in dogs, according to Guy. Under the brand name Canalevia-CA1, crofelemer previously received MUMS designation for CID in dogs.

“We believe [Crofelemer] also meets the requirements for MUMS designation for our planned EID indication in dogs," said Guy in the release.

Jaguar Animal Health is anticipating conditional approval from the FDA for crofelemer, under the brand name Canalevia-CA2, for treatment of EID in dogs in the fourth quarter of 2022.

Advertisement

Crofelemer is should only be used by or on the order of licensed veterinarians. The most reported adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Reference

Jaguar Animal Health seeks MUMS designation from FDA for Canalevia (Crofelemer) for treatment of exercise-induced diarrhea (EID) in dogs. News release. Jaguar Animal Health. February 16, 2022. Accessed February 16, 2022. https://jaguarhealth.gcs-web.com/news-releases/news-release-details/jaguar-animal-health-seeks-mums-designation-fda-canalevia

Related Content:

GastroenterologyPharmacyOncologyBusinessFDA
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
PetHub launches AI tools for pet owners
PetHub launches AI tools for pet owners
AmeriVet Veterinary Partners deemed one of 2023's Top Places to Work
AmeriVet Veterinary Partners deemed one of 2023's Top Places to Work

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement